Phase Ib/II study of LEE011, everolimus, and exemestane in postmenopausal women with ER+/HER2-metastatic breast cancer.
The DOI matches its Crossref record.
Abstract
535 Background: Aromatase inhibitors (AIs) are the recommended first-line endocrine therapy for postmenopausal (PM) patients (pts) with ER+/HER2– advanced/metastatic breast cancer (aBC). However, resistance develops over time. Activation of the PI3K/AKT/mTOR pathway and downstream cyclin D–cyclin-dependent kinase (CDK4/6) has been implicated in endocrine-therapy resistance. Combination of the mTOR inhibitor everolimus (EVE) with exemestane (EXE) significantly improved PFS of pts with ER+/HER2– aBC (BOLERO-2), and preclinical data suggest that combination of EXE, EVE, and the CDK4/6 inhibitor LEE011 may be even more effective in endocrine-resistant ER+/HER2– BC. Methods: During Phase (Ph) Ib, PM pts with ER+/HER2– aBC are being treated with escalating doses of LEE011 (3 wks on/1 wk off), EVE (continuous), and a fixed daily dose of EXE (25 mg/d; continuous; arm 1); or with a safety run-in of LEE011 (600 mg/d; 3 wks on/1 wk off) and EXE (25 mg/d; continuous; arm 2) to confirm the recommended Ph II dose (RP2D). The primary objective of the Ph Ib part of the study is to determine the maximum tolerated dose and/or RP2D in arm 1. Safety, tolerability, and PK will also be assessed. Dose escalation is guided by a Bayesian Logistic Regression Model (BLRM) with overdose control principle. Results: As of Dec 12, 2013, 6 pts have been treated in arm 1 with 200 mg/d LEE011, 2.5 mg/d EVE, and EXE, and among the 5 pts evaluable for dose determination, no DLTs were observed. AEs observed to date have been mainly hematologic (as expected with a CDK 4/6 inhibitor) and mild to moderate.Preliminary PK suggest that LEE011 exposure in the presence of EVE is similar to that of single agent, while for EVE there was a 2-fold increase in exposure at steady state.Pts are currently being treated in arm 1 cohort 2 (300 mg/d LEE011, 2.5 mg/d EVE, and EXE) and in arm 2. Conclusions: To the best of our knowledge, this is the first trial evaluating an AI in combination with an mTOR and a CDK4/6 inhibitor. Preliminary data suggest that the triple combination of LEE011 + EVE + EXE is feasible. The exposure of EVE is slightly increased. In Ph II of the study, pts will be randomized to receive LEE011 + EVE + EXE, LEE011 + EXE, or EVE + EXE, and safety and efficacy compared. Clinical trial information: NCT01857193.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment
VanArsdale, T., Boshoff, C., Arndt, K. T., & Abraham, R. T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0816 · Cited by 396
“This scenario has prompted implementation of triple combination studies involving the addition of a PI3K or mTOR inhibitor to the established antihormonal plus CDK4/6 inhibitor regimens (55).”
MethodTripathy, D., Bardia, A., & Sellers, W. R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3157 · Cited by 247
“The most common AEs were hematologic, and Grade 3/4 neutropenia was frequent but uncomplicated (42, 44-46).”
Self-citation
Metadata
- Authors
- Bardia, A., Modi, S., Chavez-Mac Gregor, M., Kittaneh, M., Marino, A. J., Matano, A., Bhansali, S., Hewes, B., & Cortes, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2014-05-20
- Volume
- 32
- Issue
- 15_suppl
- Pages
- 535-535
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2529242108
- Cited by
- 23
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase Ib/II study of LEE011, everolimus, and exemestane in postmenopausal women with ER+/HER2-metastatic breast cancer. https://app.cochat.ai/papers/10.1200/jco.2014.32.15_suppl.535
- The paper
- Bardia, A., Modi, S., Chavez-Mac Gregor, M., Kittaneh, M., Marino, A. J., Matano, A., Bhansali, S., Hewes, B., & Cortes, J. (2014). Phase Ib/II study of LEE011, everolimus, and exemestane in postmenopausal women with ER+/HER2-metastatic breast cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2014.32.15_suppl.535
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.